Eukaryotic Release Factor (eRF)

真核释放因子 (eRF) 通过识别终止密码子并促进肽酰-tRNA 水解,直接终止蛋白质生物合成[1][2]。机制上,eRF1 识别 UAA、UAG 和 UGA 终止密码子,而 eRF3 作为 GTPase 与 eRF1 协同,促进快速多肽释放[2][3]。在 mRNA 质量控制中,eRF1 和 eRF3 还参与 SMG1-UPF1-eRF1-eRF3 组成的 SURF 复合物,并连接无义介导的 mRNA 降解过程[4]。在疾病模型中,提前终止密码子读通被用于研究由无义突变导致的遗传病,eRF3 降解可增强 G418 诱导的读通并影响 NMD 相关蛋白水平[5]。与 eRF3b 相比,eRF3a 沉默在人体细胞中显著增加提前无义密码子读通,而 eRF3b 过表达可补偿 eRF3a 降低造成的终止缺陷[6]。因此,eRF3a 和 eRF3b 不是完全等效的终止因子同工型,eRF3a 主要维持哺乳动物翻译终止复合物形成和 eRF1 稳定性[6]。实验应用中,CC-90009、CC-885 和 SJ6986 等 eRF3a 降解剂可作为研究提前终止密码子读通和 CFTR 无义突变功能恢复的工具[5][7]。

Eukaryotic release factors terminate protein biosynthesis by recognizing stop codons and promoting peptidyl-tRNA hydrolysis on the ribosome[1][2]. Mechanistically, eRF1 recognizes UAA, UAG, and UGA stop codons, whereas eRF3 acts as a GTPase that cooperates with eRF1 to accelerate nascent polypeptide release[2][3]. In mRNA quality control, eRF1 and eRF3 also participate in the SMG1-UPF1-eRF1-eRF3 SURF complex that links translation termination to nonsense-mediated mRNA decay[4]. In disease models, premature termination codon readthrough provides an experimental route for studying nonsense-mutation disorders, and eRF3 degradation enhances G418-induced readthrough while altering NMD-related protein levels[5]. Compared with eRF3b, eRF3a silencing markedly increases premature nonsense codon readthrough in human cells, while eRF3b overexpression compensates for termination defects caused by eRF3a depletion[6]. Therefore, eRF3a and eRF3b are not fully equivalent release-factor isoforms, because eRF3a mainly maintains mammalian termination-complex formation and eRF1 stability[6]. For experimental applications, eRF3a degraders including CC-90009, CC-885, and SJ6986 support studies of premature stop codon readthrough and CFTR nonsense-mutation rescue[5][7].eRF research connects translation termination, stop codon recognition, GTP hydrolysis, and nonsense-mediated decay.
eRF3a and eRF3b isoform differences guide mammalian termination-complex and readthrough experiments.
eRF3a degraders support CFTR nonsense mutation rescue and premature stop codon readthrough studies.

By Effects: Degrader (1)
共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
PROTAC erf3a Degrader-1

PROTAC erf3a Degrader-1(Compound C63)是一种具有口服活性的 PROTAC erf3a 降解剂,可抑制癌细胞(如 22Rv1)的增殖,并可用于前列腺癌、卵巢癌、肝癌、宫颈癌、白血病、乳腺癌等癌症的研究(粉色:eRF3a/GSPT1 靶蛋白配体;蓝色:Cereblon 配体 (MS-V29738);黑色:连接子 (MS-L79395))。

3033871-19-8
Degrader
99.44%
PROTAC erf3a Degrader-1

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础